Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026 22:00:00
OSR Holdings Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
0,496 7,36 0,03 258 179
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiOSR Holdings Inc
TickerOSRH
Kmenové akcie:Ordinary Shares
RICOSRH.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.09.2025
Akcie v oběhu k 26.01.2026 25 757 126
MěnaUSD
Kontaktní informace
Ulice10900 Ne 4Th Street, Suite 2300
MěstoBELLEVUE
PSČ98004
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon14 256 357 700

Business Summary: OSR Holdings, Inc. is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, it is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its operating businesses include developing oral immunotherapies for the treatment of cancer, developing design-augmented (DA) biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. Its subsidiaries include VAXIMM AG (Vaximm); RMC Co., Ltd. (RMC); Darnatein Co., Ltd. (Darnatein), and Woori IO Co., Ltd. (Woori IO). Vaximm is developing oral immunotherapies for the treatment of cancer and immunological disorders. RMC is a Korea-based neurovascular intervention medical device and systems distribution company. Darnatein is developing DA biologics for age-related and other degenerative diseases. Woori IO is a South Korea-based medical device company.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, OSR Holdings Inc revenues decreased 3% to $2.5M. Net loss applicable to common stockholders increased 47% to $13.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other expenses increase from $145K to $9.4M (expense), General and administrative expenses increase of 16% to $12.4M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSMedical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
NAICSTrusts, Estates, and Agency Accounts
NAICSOther Financial Vehicles
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Other Financial Vehicles
NAICS1997Other Financial Vehicles
SICMedical And Hospital Equipment
SICCommercial Physical Research
SICInvestment Offices, Nec
SICTrusts, Nec
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerKuk Hyoun Hwang5014.02.2025
Chief Financial OfficerGihyoun Bang4714.02.202514.02.2025
Chief Scientific OfficerConstance Hofer5624.03.202524.03.2025
Chief Legal Officer, Company Secretary, DirectorJun Chul Whang6114.02.202514.02.2025